Key Developments: Virbac SA (VIRB.PA)

VIRB.PA on Paris Stock Exchange

11:35am EDT
Price Change (% chg)

€-3.45 (-2.17%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Virbac to propose terms of share repurchase program
Thursday, 22 May 2014 11:21am EDT 

Virbac SA:To propose terms of share repurchase program to annual general meeting on June 17.Taking into account shares already held by company, program would authorize repurchase of up to 816,298 shares, or 9.7 pct of share capital.Maximum price per share 300 euros.Total maximum that could be spent 244,889,400 euros.Authorization valid for 18 months.  Full Article

Virbac proposes FY 2013 dividend
Wednesday, 19 Mar 2014 12:45pm EDT 

Virbac SA:Proposes unchanged FY 2013 dividend of 1.90 euro per share, paybale on June 25.  Full Article

Virbac SA Announces Details of Share Repurchase Program
Tuesday, 4 Jun 2013 03:28am EDT 

Virbac SA announced details of the share repurchase program which will be submitted for the approval of its Annual General Meeting on June 17, 2013. The Company currently holds 29,695 of its own shares, that is 0.35% of the share capital. The Company may repurchase a maximum of 10% of its, share capital. Taking into account the shares already held by the Company, the maximum number of shares which may be repurchased as part of the program is 816,105. The maximum price per share is EUR 250, and the total maximum which may be spent on the program is EUR 204,026,250. If approved, the program will run for a period of 18 months.  Full Article

NovaBay Pharmaceuticals Inc And Virbac SA Enter Into Collaboration And License Agreement For Animal Health
Tuesday, 28 May 2013 03:05am EDT 

NovaBay Pharmaceuticals Inc announced that it has entered into a collaboration and license agreement with Virbac SA, a global veterinary product company. Virbac exercised its March 2012 Feasibility and Option Agreement, thereby acquiring exclusive worldwide rights to develop NovaBay's compound, auriclosene (NVC-422), for global veterinary markets. NovaBay will receive an option exercise fee as well as development and pre-commercial payments as a result of the collaboration. NovaBay also expects to receive royalties on the sale of any commercial products in the companion animal field. Virbac's option exercise follows its testing of auriclosene for veterinary uses during the 12-month option period.  Full Article

Virbac SA Comment On FY 2013 Guidance
Tuesday, 16 Apr 2013 11:50am EDT 

Virbac SA announced that it expects to report 5% to 7% organic growth and a further 0.5 point improvement of operating profitability in fiscal year 2013. The Company also expects to report a double digit growth of its revenues and operating profit in full year 2013.  Full Article

Virbac SA Issues FY 2013 Organic Growth and Operating Profitability Guidance; Proposes FY 2012 Dividend
Monday, 11 Mar 2013 12:50pm EDT 

Virbac SA announced that it expects 5 to 7% organic growth and a further 0.5 point improvement of operating profitability in fiscal year 2013. The Company also announced that a dividend of EUR 1.90 per share for fiscal year 2012, as compared to EUR 1.75 in fiscal year 2011, shall be proposed at the next Annual Shareholders Meeting and will be payable on June 26, 2013.  Full Article

Virbac SA Announces Acquisition of Majority Stake in Centrovet
Friday, 23 Nov 2012 11:57am EST 

Virbac SA announced the signing of an agreement by which the Company is acquiring a majority stake in Centrovet, a Chile-based company specialized in aquaculture health products. According to this agreement, Virbac SA has purchased 51% of the shares of the Centrovet Group from its shareholders and will have the option to acquire the remaining capital stock at the end of a five year period. Financial terms of the agreement were not disclosed.  Full Article

Isconova AB Concludes Partnership Agreement with Virbac Regarding Matrix-M
Wednesday, 25 Jul 2012 01:11am EDT 

Isconova AB announced that it has concluded a partnership agreement with Virbac, a pharmaceutical company in veterinary medicine. In a first step, Isconova AB's adjuvant Matrix-M will be used by Virbac for the development and improvement of vaccines for the global veterinary market. The first products based on Matrix-M are vaccines for dogs against certain infectious diseases. Isconova AB will receive development payments and royalties based on Virbac’s future sales of these vaccines.  Full Article

Search Stocks